• Christgen M, Cserni G, Floris G, Marchio C, Djerroudi L, Kreipe H, et al. Lobular Breast Cancer: Histomorphology and Different Concepts of a Special Spectrum of Tumors. Cancers (Basel) 13, (2021)

  • Christgen M, Steinemann D, Kuhnle E, Langer F, Gluz O, Harbeck N, et al. Lobular breast cancer: Clinical, molecular and morphological characteristics. Pathol Res Pract 212, 583-97 (2016)

  • Desmedt C, Zoppoli G, Gundem G, Pruneri G, Larsimont D, Fornili M, et al. Genomic Characterization of Primary Invasive Lobular Breast Cancer. J Clin Oncol 34, 1872-81 (2016)

  • McCart Reed AE, Kalinowski L, Simpson PT, Lakhani SR Invasive lobular carcinoma of the breast: the increasing importance of this special subtype. Breast Cancer Res 23, 6 (2021)

  • Riggins RB, Lan JP, Klimach U, Zwart A, Cavalli LR, Haddad BR, et al. ERRgamma mediates tamoxifen resistance in novel models of invasive lobular breast cancer. Cancer Res 68, 8908-17 (2008)

  • Conforti F, Pala L, Pagan E, Viale G, Bagnardi V, Peruzzotti G, et al. Endocrine-responsive lobular carcinoma of the breast: features associated with risk of late distant recurrence. Breast Cancer Res 21, 153 (2019)

  • Ross JS, Wang K, Sheehan CE, Boguniewicz AB, Otto G, Downing SR, et al. Relapsed classic E-cadherin (CDH1)-mutated invasive lobular breast cancer shows a high frequency of HER2 (ERBB2) gene mutations. Clin Cancer Res 19, 2668-76 (2013)

  • Ross JS, Gay LM, Wang K, Ali SM, Chumsri S, Elvin JA, et al. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies. Cancer 122, 2654-62 (2016)

  • Christgen M, Bartels S, Luft A, Persing S, Henkel D, Lehmann U, et al. Activating human epidermal growth factor receptor 2 (HER2) gene mutation in bone metastases from breast cancer. Virchows Arch 473, 577-82 (2018)

  • Razavi P, Chang MT, Xu G, Bandlamudi C, Ross DS, Vasan N, et al. The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. Cancer Cell 34, 427-38 e6 (2018)

  • Kurozumi S, Alsaleem M, Monteiro CJ, Bhardwaj K, Joosten SEP, Fujii T, et al. Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets. Breast Cancer Res 22, 85 (2020)

  • McCart Reed AE, Foong S, Kutasovic JR, Nones K, Waddell N, Lakhani SR, et al. The genomic landscape of lobular breast cancer. Cancers (Basel) 13, 1950 (2021)

  • Aftimos P, Oliveira M, Irrthum A, Fumagalli D, Sotiriou C, Gal-Yam EN, et al. Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. Cancer Discov 11, 2796-811 (2021)

  • Bose R, Ma CX Breast Cancer, HER2 Mutations, and Overcoming Drug Resistance. N Engl J Med 385, 1241-43 (2021)

  • Croessmann S, Formisano L, Kinch LN, Gonzalez-Ericsson PI, Sudhan DR, Nagy RJ, et al. Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer. Clin Cancer Res 25, 277-89 (2019)

  • Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol 36, 2105-22 (2018)

  • Dowsett M Testing endocrine response for managing primary estrogen receptor-positive breast cancer. J Clin Oncol In press, (2022)

  • Smith I, Robertson J, Kilburn L, Wilcox M, Evans A, Holcombe C, et al. Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial. Lancet Oncol 21, 1443-54 (2020)

  • Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, A’Hern R, et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 99, 167-70 (2007)

  • Smith IE, Dowsett M, Ebbs SR, Dixon JM, Skene A, Blohmer JU, et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 23, 5108-16 (2005)

  • Nitz U, Gluz O, Kreipe HH, Christgen M, Kuemmel S, Baehner FL, et al. The run-in phase of the prospective WSG-ADAPT HR+/HER2- trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer. Ther Adv Med Oncol 12, 1758835920973130 (2020)

  • Nitz U, Gluz O, Kuemmel S, Christgen M, Braun M, Aktas B, et al. Endocrine therapy response and 21-gene expression assay for therapy guidance in HR-positive/HER2-negative early breast cancer. J Clin Oncol In press (2022)

  • Grote I, Bartels S, Kandt L, Bollmann L, Christgen H, Gronewold M, et al. TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer. Cancer Med 10, 8581-94 (2021)

  • Hofmann D, Nitz U, Gluz O, Kates RE, Schinkoethe T, Staib P, et al. WSG ADAPT – adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial. Trials 14, 261 (2013)

  • Lakhani SR, Ellis I, Schnitt S, Tan PH, van de Vijver M. (2012) WHO Classification of Tumours of the Breast. Lyon: International Agency for Research on Cancer.

  • Christgen M, Kandt LD, Antonopoulos W, Bartels S, Van Bockstal MR, Bredt M, et al. Inter-observer agreement for the histological diagnosis of invasive lobular breast carcinoma. J Pathol Clin Res 8, 191-205 (2022)

  • Parry S, Dowsett M, Dodson A UK NEQAS ICC & ISH Ki-67 Data Reveal Differences in Performance of Primary Antibody Clones. Appl Immunohistochem Mol Morphol 29, 86-94 (2021)

  • Viale G, Hanlon Newell AE, Walker E, Harlow G, Bai I, Russo L, et al. Ki-67 (30-9) scoring and differentiation of Luminal A- and Luminal B-like breast cancer subtypes. Breast Cancer Res Treat 178, 451-58 (2019)

  • Christgen M, von Ahsen S, Christgen H, Langer F, Kreipe H The region-of-interest size impacts on Ki67 quantification by computer-assisted image analysis in breast cancer. Hum Pathol 46, 1341-9 (2015)

  • Rimm DL, Leung SCY, McShane LM, Bai Y, Bane AL, Bartlett JMS, et al. An international multicenter study to evaluate reproducibility of automated scoring for assessment of Ki67 in breast cancer. Mod Pathol 32, 59-69 (2019)

  • Sahebjam S, Aloyz R, Pilavdzic D, Brisson ML, Ferrario C, Bouganim N, et al. Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score. Br J Cancer 105, 1342-5 (2011)

  • Christgen M, Gluz O, Harbeck N, Kates RE, Raap M, Christgen H, et al. Differential impact of prognostic parameters in hormone receptor-positive lobular breast cancer. Cancer 126, 4847-58 (2020)

  • Robichaux JP, Elamin YY, Vijayan RSK, Nilsson MB, Hu L, He J, et al. Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity. Cancer Cell 36, 444-57 e7 (2019)

  • Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 486, 353-60 (2012)

  • Ciriello G, Gatza ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A, et al. Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. Cell 163, 506-19 (2015)

  • Rinaldi J, Sokol ES, Hartmaier RJ, Trabucco SE, Frampton GM, Goldberg ME, et al. The genomic landscape of metastatic breast cancer: Insights from 11,000 tumors. PLoS One 15, e0231999 (2020)

  • Topics #Advanced computer #computer #Electronics #Hardware #Software